Taking stock of the drug industry, from the lab to the medicine chestAugust 7, 2025Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer Adobe STAT+ | Eli Lilly's much-anticipated obesity pill yields modest results Eli Lilly's pill candidate, orforglipron, led to 11% weight loss in a late-stage trial, far less than results from injectable obesity drugs. By Elaine Chen STAT+ | As mRNA falls out of favor for HHS, are cancer vaccines next? Oncologists worry that HHS's cutoff of mRNA research could lead to a broader hostile posture towards using mRNA and hamper cancer treatments. By Angus Chen, Megan Molteni, and Marissa Russo STAT+ | Alnylam could be the next mega-cap biotech In this edition of Adam's Biotech Scorecard, Adam also looks at three companies having a great summer: Nektar Therapeutics, Abivax, and Celcuity. By Adam Feuerstein Simon Dawson/Pool via AP STAT+ | Exact Sciences acquires rights to rival Freenome's blood-based colon cancer test The deal ratchets up Exact's intense competition with Guardant, which received FDA approval last year for its own colon cancer liquid biopsy By Jonathan Wosen STAT+ | Dewpoint Therapeutics, biotech startup in a once-buzzy field, cuts 70% of staff The company is focused on medicines using bimolecular condensates, which became a hot area of investment around 2020 but have since cooled. By Allison DeAngelis More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2025, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments